Economic evaluation of fecal microbiota transplantation for the treatment of recurrent<i>Clostridium difficile</i>infection in Australia

Abstract

If FMT, rather than vancomycin, became standard care for recurrent CDI in Australia, the estimated national healthcare savings would be over AU$4000 per treated person, with a substantial increase in quality of life.